3D Printed Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Technology (Inkjet Printing, Fused Deposition Modeling, Stereolithography, ZipDose Technology, Others), By Application (Orthopedic, Neurology, Dental, Others), By End User (Hospitals & Clincs, Academic & Research Institutions, Others), By Region

Increasing Prevalence of Chronic Diseases

According to global cancer observatory, around 19,292,789 new cancer cases were reported worldwide in 2020, with breast cancer, lung cancer, colorectum cancer, prostate cancer and stomach cancer being the most prevalent types.

Benefits Associated With 3D Printed Drugs

There are numerous benefits associated with the use of 3D Printed Drugs such as using this technique medicines can be produced in small batches with carefully tailored shapes, dosages, and sizes, among others. In addition, the use of 3D printing technology can significantly reduce manufacturing costs. This in turn is expected to increase investments in this space, thereby supporting the market growth during the forecast period. However, increased awareness of the benefits of these medications, such as their immediate solubility, faster manufacturing time, reduced waste, and easy on-demand manufacturing is likely to create multiple prospects for market growth.

Market Segmentation

The number of personalized medicines found at in the United States in 2020 were around 286.

Market Players

Aprecia Pharmaceuticals, LLC., FabRx Ltd., Merck & Co. Inc., Triastek, Inc., GlaxoSmithKline plc., Formac Pharmaceuticals N.V., AstraZeneca plc, Extend Biosciences, Inc., Affinity Therapeutics, LLC, Osmotica Pharmaceuticals Corporation